Patients with rheumatoid arthritis (RA) all have a unique and diverse set of antibodies that are involved in the development of the disease.
Abeona’s new Form 483 is another manufacturing setback for its rare skin condition asset
Abeona Therapeutics was handed a Form 483 “related to process controls” for its epidermolysis bullosa candidate in a second manufacturing-related roadblock for the program, with